Singapore: AUM Biosciences going public through SPAC merger

Singapore-based AUM Biosciences, a clinical-stage biotechnology company, is listing on Nasdaq following a merger with blank cheque company Mountain Crest Acquisition Corp V. The transaction, expected to close in the first quarter of 2023, reflects an equity value for AUM of US$400m and will provide the company with approximately US$69m of cash held in Mountain…

You must be a HMI Subscriber to view this content.

Subscribe Now »